Phase 3Completed

Bentracimab in Ticagrelor-treated Patients With Uncontrolled Bleeding or Requiring Urgent Surgery or Invasive Procedure (REVERSE-IT)

A Phase 3, Multicenter, Open-Label, Single-Arm Study of Bentracimab (PB2452) in Ticagrelor-Treated Patients With Uncontrolled Major or Life-Threatening Bleeding or Requiring Urgent Surgery or Invasive Procedure (REVERSE-IT Trial)

Sponsor
SFJ Pharmaceuticals, Inc. (Industry)
Enrollment
226 enrolled
Conditions
Hemorrhage; Urgent Surgery; Invasive Procedure
Interventions
Bentracimab (PB2452) Infusion
Ages
adults, older adults
Registry
NCT04286438, EUCTR2019-004457-92

Full record on ClinicalTrials.gov

From the registry

This is a multi-center, open-label, prospective single-arm study of reversal of the antiplatelet effects of ticagrelor with bentracimab (PB2452) in patients who present with uncontrolled major or life-threatening bleeding or who require urgent surgery or invasive procedure. At least 200 patients will be enrolled from approximately 200 centers in North America, Europe, and Asia-Pacific regions, including mainland China. Patients with reported use of ticagrelor within the prior 3 days who require urgent ticagrelor reversal will be eligible for enrollment. These populations will be enrolled based on separate inclusion criteria.

Primary outcomes

  • Reversal - Platelet Reactivity Units (PRU)
  • Hemostasis - Uncontrolled major of life-threatening bleeding - Achievement
  • Hemostasis - Urgent surgery or invasive procedure - Achievement

History

  1. Last registry update

  2. Primary completion

  3. Started

  4. Registered